ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2466

Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease

Francesco Del Galdo1, Lesley-Anne Bissell2, Rozeta Simonovska3 and Margarida Alves4, 1University of Leeds, Leeds, United Kingdom, 2Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, 4Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany

Meeting: ACR Convergence 2024

Keywords: interstitial lung disease, Outcome measures, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in patients with early diffuse cutaneous SSc (dcSSc) [Khanna D et al. Arthritis Rheumatol 2016;68:299-311]. The revised CRISS calculates the proportion of patients who improve based on core measures, but does not discriminate non-improvement from worsening. With engagement from 180 patients and expert physicians, a continuous ranked composite important difference (RCID) score was developed to differentiate non-improvement from worsening, and to measure overall outcome, based on weighting minimal clinical important differences (MCIDs) in core CRISS domains [Bissell L et al. Arthritis Rheumatol 2022;74(suppl 9):0523]. We evaluated RCID scores in patients with dcSSc and interstitial lung disease (ILD) who participated in the SENSCIS trial.

Methods: The SENSCIS trial enrolled patients with SSc-ILD with first non-Raynaud symptom in the prior ≤7 years and an extent of fibrotic ILD on HRCT ≥10%. Patients on prednisone ≤10 mg/day (or equivalent) and/or stable therapy with mycophenolate or methotrexate were allowed to participate. Patients were randomised to receive nintedanib or placebo. RCID scores over 52 weeks were calculated in the patients with dcSSc (overall and in subgroups by mycophenolate use). These scores were based on four components (organ failure, forced vital capacity [FVC] % predicted, modified Rodnan skin score [mRSS], Health Assessment Questionnaire Disability Index [HAQ-DI]) (Table) and ranged from -100% (worst outcome) to 100% (best outcome).

Results: In the placebo and nintedanib groups, respectively, mean (SD) RCID scores over 52 weeks were ‑3% (36) (n=119) and 4% (36) (n=117) overall, 3% (38) (n=60) and 7% (36) (n=60) among those taking mycophenolate at baseline, and ‑10% (31) (n=59) and < 1% (35) (n=57) among those not taking mycophenolate at baseline. Accordingly, a greater proportion of patients had stable or improved RCID scores (i.e. ≥0%) in the nintedanib group than the placebo group overall and in subgroups by use of mycophenolate (Figure 1). The proportions of patients with worsening of FVC % predicted was smaller in the nintedanib group than the placebo group overall (23.5% vs 41.8%) and in subgroups by use of mycophenolate (Figure 2). The proportions of patients with worsening/stability in other components of the RCID score were similar between the placebo and nintedanib groups (Figure 2).

Conclusion: Among patients with dcSSc and ILD in the SENSCIS trial, physician and patient-determined RCID scores were better overall in the nintedanib group than in the placebo group, mainly driven by reduced decline in FVC over 52 weeks.

Supporting image 1

Table. Weighting of criteria to calculate RCID score.

Supporting image 2

Figure 1. Frequency distribution of RCID scores over 52 weeks in patients with dcSSc and ILD in the SENSCIS trial overall and in subgroups by use of mycophenolate at baseline. Analysed in patients with non-missing RCID scores.

Supporting image 3

Figure 2. Proportions of patients with worsening, stability, or improvement in RCID components over 52 weeks in patients with dcSSc and ILD in the SENSCIS trial (A) overall and (B) in subgroups by use of mycophenolate at baseline.


Disclosures: F. Del Galdo: AbbVie, 2, 5, Argenx, 2, Arxx, 2, 5, AstraZeneca, 2, 5, Boehringer Ingelheim, 2, 5, Chemomab, 5, Deepcure, 2, GlaxoSmithKline (GSK), 2, Janssen, 2, Mitsubishi Tanabe, 5, Novartis, 2, Ventus, 2; L. Bissell: AbbVie, 6, Alfasigma, 6, Galapagos, 6, UCB, 6; R. Simonovska: Boehringer Ingelheim, 7; M. Alves: Boehringer Ingelheim, 3.

To cite this abstract in AMA style:

Del Galdo F, Bissell L, Simonovska R, Alves M. Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/ranked-composite-important-difference-rcid-scores-in-patients-with-diffuse-cutaneous-systemic-sclerosis-and-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ranked-composite-important-difference-rcid-scores-in-patients-with-diffuse-cutaneous-systemic-sclerosis-and-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology